ArticleJournal of immunology (Baltimore, Md. : 1950)2021

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Claire L Langrish et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.